Index
- Abbott Molecular
- AbbVie
- Abilify (aripiprazole)
- accountable care organizations (ACOs)
- active ingredient-based groups
- Actonel (risedronate)
- Actos (pioglitazone)
- acute myeloid leukemia (AML)
- Aetna, commercial insurers
- affordability
- of prescription drugs
- up-front of medicine
- Affordable Care Act (ACA)
- Afrezza inhaler
- AG-221 (enasidenib)
- AgaMatrix
- Agency for Healthcare Research and Quality (AHRQ)
- Aggarwal, R
- agile supply chain, creating
- algorithms
- Bayesian
- AliveCor
- alliance. see also strategic alliances
- acquisition continuum
- biotech companies
- Celgene
- contract
- contractual
- arrangement
- pharma companies
- transactions
- Alnylam
- cash raising
- financing strategies
- funding
- RNA interference (RNAi) based therapies
- Alphabet
- healthcare portfolio
- ALS (amyotrophic lateral sclerosis)
- Alzheimer’s disease
- Amazon
- American Lung Association
- American Society of Clinical Oncologists’ (ASCO) Value Framework
- American Telemedicine Association (ATA)
- accreditation
- American Well
- AmeriDoc
- Amgen
- amyotrophic lateral sclerosis (ALS)
- analytics
- across biopharma value chain
- continuum
- descriptive
- driven organization
- enabled biopharma organization
- first organization building
- as strategic imperative
- changing behaviors
- partner for flexibility
- role in establishing product value
- to rethink commercial activities
- anaplastic lymphoma kinase
- Anthem
- antibiotic
- development
- inappropriate use
- research
- Apache Hadoop
- Apple
- Apple iTunes
- Apple ResearchKit
- Apple Watch
- Aprecia Pharmaceuticals
- artificial intelligence (AI)
- Aspinall, Mara
- AstraZeneca
- scheme
- Australian Pharmaceutical Benefits Advisory Committee (PBAC)
- Avalere/Faster Cures’ Patient Perspective Value Framework
- Baris, Aris
- benefit/cost ratio
- beyond the pill
- beta thalassemia
- biannual price
- big data
- Bill and Melinda Gates Foundation
- Biogen
- biomarkers
- development
- targeted medicines
- biometric sensor
- biopharma
- best practices for
- digital strategies
- new R & D patient-centric models
- optimizing clinical trials
- role of social media in trials
- divesting
- marketing strategy
- organizational models
- payer relationships
- pricing model
- strategic alliances
- dealing for
- mission and objectives
- monitoring results and learning
- partner selection
- structure
- drivers and constraints
- innovation
- meeting commercial needs
- vs. acquisition
- dealing for
- structure considerations
- to become analytics experts, multiple forces
- trust-breakers
- value chain
- biopharma-payer engagement
- chronic, high-cost diseases
- and outcomes-based deals
- data co-creation with payers leads to
- integrated payers
- scaling-up new partnership models
- chronic, high-cost diseases
- biopharmaceutical
- companies (see biopharma)
- products
- biosensors
- biosimilars
- challenge of
- developing
- from Lilly and Boehringer Ingelheim
- value proposition associated with
- biotech company/entrepreneurs
- business model
- commercialization
- funding sources, and representative amounts, (see also financing sources)
- fundraising, geographic considerations
- mergers and acquisitions
- patient engagement capabilities
- R & D support payments
- biotechnology
- industry applications
- megatrends impact
- Biotechnology Innovation Organization (BIO)
- Blin, Emmanuel
- blue biotech
- Blue Gene supercomputer
- Boniva (ibandronate)
- Bosley, Katrine
- BrainBaseline cognitive software
- brand
- generics
- loyalty
- medicines
- models
- Brilinta (ticagrelor)
- Bristol-Myers Squibb
- employee engagement initiative
- goals
- program development
- globally relevant
- internally focused
- program launch
- storytelling, power of
- strategy
- budget
- constraints
- discipline
- bundled payment
- experiments, selected
- models
- business
- development
- models
- business-to-business (B to B) model
- Bydureon (XR exenatide)
- Calico
- campaigns
- CancerCare
- cancer treatment
- chemotherapy
- radiation therapy
- capital preservation, adaptations to
- capital raising
- biotech management teams
- strategic decisions
- pricing and dilution
- capital, sources
- corporate venture capital
- crossover investment funds
- governments and disease foundations grants
- larger pharmaceutical/biotechnology companies, collaborations with
- public investors
- seed stage investors
- venture capital firms
- cardiometabolic syndrome
- CDC (Centers for Disease Control and Prevention)
- Celgene
- Centers for Medicare and Medicaid Services (CMS)
- Cerezyme (imiglucerase)
- Charpentier, Emanuelle
- chemotherapy
- Chick, Stephen
- chief data officer (CDO)
- chief information officer (CIO)
- chief patient officer
- chronic myeloid leukemia
- Cigna
- Cleveland Clinic
- Clinical Commissioning Groups
- Clinical Educator Programs
- clinical trial
- consent forms
- enhancement
- improving
- patient-to-patient communications
- trial optimization
- cloud computing
- cloud-based storage
- collaborations
- combination products
- commercial insurers
- commercial risks
- commercialization costs
- companion diagnostics
- competition
- competitors
- consumer
- attitudes
- centered trends
- decision journey
- social media
- wearables
- empowerment
- Web-driven
- engagement
- focused healthcare loans
- information gaps
- pricing
- research
- content marketing
- continuous glucose monitoring (CGM) device
- cost control
- cost-effectiveness
- analyses
- cost-of-illness modeling
- cost-sharing
- Coulter, Martin
- Crestor (rosuvastatin)
- Crick, Francis
- CRISPR/Cas9 technology
- cross-functional teams
- cultural barriers
- curative therapies
- custom-built IBM apps
- cutting-edge technologies
- CVS Health Corp.
- cystic fibrosis
- drugs
- Cystic Fibrosis Foundation
- Dana-Farber Cancer Institute
- data
- analysis
- analytics
- and analytics challenges
- capabilities
- driven solutions
- generation
- integration
- lifestyle
- mining process
- privacy
- quality
- sharing
- data breaches
- Davidovic, David
- debt-financing instruments
- decision-making power
- democratization
- department-specific key performance indicators (KPIs)
- Dexcom
- diabetes
- diagnostics developers
- drug developers, deal making between
- digital biomarkers
- digital communications
- metrics for
- digital engagement tools
- digital ethnography tools
- digital health
- landscape
- opportunities
- strategies
- digital impact on supply chain management
- digital markers, in diabetes
- digital medicines
- digital precision medicine
- digital services, scope of
- digital technologies
- digital tools
- digital transformation, of commercial activities
- direct-to-consumer (DTC)
- advertising
- promotion
- disease
- management services
- outcomes
- prevention accelerator
- DNAnexus
- doctor on demand
- virtual services
- Doudna, Jennifer
- 3D printing
- drug costs
- drug developers
- drug development
- efforts
- product approval
- drug discovery
- drug facts box
- drug formulations
- drug interactions
- drug manufacturers
- drug marketing
- drug pricing
- challenges
- decisions
- economics of
- inflation
- drug recalls
- drug regulators
- drug resistance
- drug spending
- drug therapy
- drug-diagnostic
- combinations
- pairs
- drug-resistant microbial infections
- drugs targeting
- dRx Capital
- DTC/direct to consumer spending
- dual branding models
- dynamic
- data market
- financing environment
- e-consultations
- e-patients
- economic drivers
- economic models
- EGFR. see epidermal growth factor receptor (EGFR)
- EHRs. see electronic, health records (EHRs)
- electronic
- consent process
- health records (EHRs)
- data
- employee incentives
- employers
- ACA strengthened federal government’s role
- drive harder bargain with
- variance
- vertical integration
- Entresto (sacubitril/valsartan)
- enzyme replacement therapies
- epacadostat
- eParticipants
- epidermal growth factor receptor (EGFR)
- expression
- inhibitor
- epigenome
- epinephrine injection
- EpiWatch app
- equity capital
- ertugliflozin(insulin glargine)
- European Medicines Agency (EMA)
- European Patients Academy on Therapeutic Innovation (EUPATI)
- European Patients Forum
- European payers
- European Union
- payers characteristics
- high-level unity, low-level fragmentation
- portfolio of pricing controls
- RareConnect site
- variations to manage drug prices/costs
- payers characteristics
- EURORDIS (European Organization for Rare Diseases)
- Everyday Health
- evidence-based marketing
- evidence-based medicine
- evidence-based strategy
- evolocumab
- experimental pricing strategies
- indication-specific pricing
- external reference pricing
- exubera
- Fabrazyme (agalsidase alfa)
- Farxiga (dapagliflozin)
- Federal Trade Commission (FTC)
- financial-based agreements (FBAs)
- financing and capital allocation strategy
- financing sources
- asset-based financing
- corporate venture capital
- crossover investors
- government grants and disease foundations
- mergers and acquisitions, role of
- private philanthropic sources
- public investors
- IPO process
- seed capital
- angel investors
- crowdfunding
- government grant
- strategic alliances
- venture capital
- venture debt
- Fitbit
- wristband sensor
- Fit2Me website
- fixed price
- fluorescent reporter protein
- Food and Drug Administration (FDA)
- alliance with the PatientsLikeMe online community
- approval of Keytruda
- approved Amgen and Sanofi/Regeneron's PCSK9 inhibitors
- approved medical devices
- approved Neupogen indications
- development and validation of PROs
- digital health unit
- encouraging biomarker-driven approaches
- Foschini, Luca
- Fouse, Jacqualyn
- franchise building
- Franklin, Rosalind
- Frazier, Kenneth
- future investors
- Galvani Bioelectronics
- Garfield, Susan
- gene
- mutations
- sequencing optimization
- sequencing technologies
- Genentech
- generic drugs
- genetic data
- genetic markers
- genome sequencing
- genomic screening
- genomic technologies
- genotype-specific oral therapy
- Genzyme
- Gilead
- Gleevec (imatinib)
- Gleevec(from Novartis)
- global financial crisis 2008
- global organization
- global price
- band
- regulation
- GlucoSuccess
- GNS Healthcare
- golden rice
- Google Flu Trends (GFT)
- Google Health
- Google mobile apps
- Google Play
- government-funded systems
- Grail
- green biotech
- group purchasing organizations (GPOs)
- GSK (Glaxo SmithKline)
- Hack Epilepsy
- Harvard Pilgrim’s outcomes-based deal
- Harvard Pilgrim Health Care
- Harvoni (ledipasvir/sofosbuvir)
- HCAHPS (Hospital Consumer Assessment of Healthcare Providers and Systems) survey
- health apps
- health data
- collected on Apple devices
- consumer-generated
- easily quantified through
- volume, variety, and velocity of
- health ecosystem
- health exchanges
- health expenditure
- Healthgrades
- health insurance
- health plans
- online shopping for
- health technology assessment (HTA)
- criteria
- healthcare
- big infotech strategies
- Alphabet healthcare portfolio
- Apple and IBM in Japan
- Apple, role of
- Calico partnerships
- Galvani bioelectronics
- Google investments
- Google search and mayo clinic
- IBM, role of
- Medtech and pharma alliances
- Qualcomm, role of
- Verily partnerships
- Watson partnerships
- business model variance
- costs
- data vectors
- data, explosion of
- digitization of
- infotech, disruption risk from
- infotechnology initiatives
- reimbursement
- technology strategies
- new entrants
- wearables, rise and limitations of
- transforming forces
- value chain, impact of digital solutions
- big infotech strategies
- HealthKit software
- HealthUnlocked
- hepatitis C
- medicine
- Herceptin (trastuzumab)
- Heywood, Ben and Jamie
- high drug prices
- high-level unity
- high-price/high-value product
- high-price/low-value product
- high-value data
- Hill, Colin
- HIPAA (Health Insurance Portability and Accountability Act)
- hospitalizations
- hospital rankings
- human epidermal growth factor receptor 2 (HER2)
- Human Genome Project
- Humira (adalimumab)
- hypertension management program
- IBM
- developed apps
- IBM Watson
- Icahn Institute for Genomics and Multiscale Biology
- ICarbonX
- Illumina
- Immunotherapeutics
- incentives
- Incivek (telaprevir)
- Incyte
- indication-specific pricing
- information technology (IT)
- infotech companies
- customer/end user
- economics
- product or service
- technology
- validation
- inhaler
- initial public offerings (IPOs)
- US and European biotechnology
- innovation
- partnership
- Institute for Clinical and Economic Review (ICER)
- insulin autoinjector
- insulin pump
- intellectual property
- intelligent supply chain
- InterMountain Healthcare
- Internet of Things (IoT) devices
- investment, see also potential investor
- bankers
- in Aurora
- in digital health
- joint
- minority
- return on
- rising
- traditional model
- venture
- Invokana (canagliflozin)
- IPO
- investors types
- dedicated specialist investment funds
- generalist investors
- journey
- shares offered
- investors types
- Iressa (gefitinib)
- Jakafi (ruxolitinib)
- Janssen
- Janumet (sita-metformin)
- Januvia (sitagliptin)
- Japan
- direct and indirect price controls
- generic reimbursement prices
- Jardiance (empagliflozin)
- Johns Hopkins
- Johnson & Johnson
- joint steering committee (JSC)
- joint ventures (JVs)
- JSC. see joint steering committee (JSC)
- Jumpstart Our Business Startups (JOBS) Act
- Juntado, Ryan
- Juvenile Diabetes Research Foundation (JDRF)
- JVs. see joint ventures (JVs)
- Kaiser Permanente
- Kalydeco (ivacaftor)
- key account managers (KAMs)
- key opinion leaders (KOLs)
- Keytruda (pembrolizumab)
- killer app
- Lantus (insulin glargine)
- launch strategies
- Leukemia and Lymphoma Foundation
- leverage
- big data
- data’s four vectors, enabling tools to
- Lilly
- Lipitor (atorvastatin)
- liquid biopsy
- loan products
- Longman, Roger
- low-density lipoprotein(LDL)
- low-level fragmentation
- low-price/high-value product
- low-price/low-value product
- machine learning
- causal
- management teams
- Managing the 360
- Maraganore, John
- market intelligence
- market research
- Massachusetts Institute of Technology
- Mathers, Ed
- Mayo Clinic
- Mazzei, Chris
- MDLive
- Medicaid
- prices
- programs
- medical
- apps
- benefits
- needs
- medical science liaisons (MSLs)
- Medicare
- Medidata Solutions
- Medscape Professional Network
- Medtronic
- Memorial Sloan Kettering’s Drug Abacus
- Merck
- Merck Manual
- metabolome
- Mevacor (lovastatin)
- M2Gen
- microbiome
- Microsoft’s Cloud
- Miller, Steve
- Miller, Tom
- mining metadata
- mobile
- appointment scheduling
- electrocardiogram (ECG) device
- medical device
- technologies
- mobile health (mHealth)
- evolution of
- Mount Sinai
- MSLs. see medical science liaisons (MSLs)
- multi-omics analysis
- multichannel communications
- multidisciplinary practice units
- multiple forces
- multiple myeloma
- multiple sclerosis
- myelodysplastic syndrome (MDS)
- Myozyme (alglucosidase alfa)
- Nadauld, Lincoln
- National Academy of Medicine (NAM)
- National Cancer Institute
- National Comprehensive Cancer Network’s Evidence Blocks
- National Health Insurance (NHI)
- National Health Service (NHS)
- National Health Technology Assessment (HTA) agencies
- National Institutes of Health (NIH) research
- National Quality Forum (NQF)
- natural language
- Netflix
- Neupogen (filgrastim)
- new drug
- and data analytics
- and price-sensitive therapy
- application filing
- distribution platforms
- positioning
- prelaunch sales expectations
- time to discover and develop
- new market
- and payer power
- force increase payer power
- science
- next-generation sequencing
- nondilutive capital
- nongovernment US payers
- non-small cell lung cancer (NSCLC)
- Novartis
- Novo Nordisk
- nurse-staffed call centers
- observational studies
- off-label therapy
- Omada Health
- Omnitrope
- OnePath program
- online discussions sites
- online healthcare information
- online patient communities
- PatientsLikeMe
- Online shopping, for health plans
- Opdivo (nivolumab)
- open innovation strategies
- alliances with academia
- alliances with external venture groups
- crowdsourcing
- innovation hubs
- open-label studies
- optimized customer penetration
- O'Reilly, Michael
- Organisation for Economic Co-operation and Development
- organizational barriers
- organizational structures
- Orkambi (lumacaftor/ivacaftor)
- Orphan Drug Act
- Orphan Medicinal Products Committee
- Oscar Health
- OSE Immunotherapeutics
- Otsuka
- outcome-based
- partnerships
- pricing experiments
- reimbursement
- over-the-counter drugs
- Parkinson's disease
- Partners Healthcare
- patent protection
- patient
- adherence
- centric ecosystem
- engagement
- initiatives
- metrics
- engagement tools, impact of
- friendly delivery systems
- identification
- insight research
- management
- registries
- satisfaction
- ratings
- value pathway
- diabetes case
- Patient Access and Engagement Report
- patient advocacy
- patient centricity
- crowdsourcing initiatives
- drivers and barriers
- forces impacting
- framework
- organization models
- structure options
- organizing for
- points of care, connecting
- engagement, biopharma initiatives for
- patient satisfaction ratings
- physician/patient dynamics
- strategies in R & D
- patient engagement
- metrics
- Patient Focused Medicines Development Initiative (PFMD)
- patient journey
- adherence strategies
- behavior, drivers and barriers of
- follow-up surveillance
- patient key opinion leaders (KOLs)
- patient-friendly clinical trials
- designing
- patient-reported outcomes (PRO)
- rare disease trials
- trial recruitment and retention
- designing
- patient-reported outcomes (PROs)
- comparative drug effectiveness
- PatientsLikeMe
- alliance strategy
- business model evolution
- challenges
- competitive dynamics
- disease-specific registries
- focus vs. scale
- grants
- health data platform, as
- partnerships
- patient forum to personalized health platform
- patient-centric care decisions
- trial optimization, role in
- virtual trials
- PatientsLikeMe website
- pay-for-performance arrangement
- payer engagement strategies
- geospatial mapping tools
- information technology (IT) infrastructure
- mapping payers based on behaviors and preferences
- strategic payer segmentation and engagement
- payer segmentation
- payer-driven patient segmentation
- Pehl, Michael
- performance-based agreements (PBAs)
- personalized care manager
- Pfizer
- pharma-biotech alliance
- pharmacodynamic marker
- Pharmacovigilance Risk Assessment Committee
- pharmacy benefit managers (PBMs)
- drug costs consideration in isolation
- problem
- profitability
- Physician Compare
- physician digital trends
- physician ratings
- platinum glucose sensor
- Plavix (clopidogrel)
- P-medicine
- point-of-care tools
- policymakers
- pollution-eating bacteria
- Pompe disease
- portfolio diversification
- postmarketing surveillance
- potential investor
- factors affecting
- fund age
- future rounds
- investment philosophy
- relevant experience
- factors affecting
- Pothier, Kristin
- Praluent (alirocumab)
- pre-digital age
- precision genomics, for cancer
- precision marketing
- strategy
- precision medicine
- alliances in
- biopharma’s engagement
- commercial challenges
- data collection
- diagnostic-driven
- focused start-ups
- forces driving
- genomics-driven
- in practice
- infrastructure challenges
- molecular-driven
- regulatory challenges
- scientific and clinical challenges
- stakeholder expansion in
- targeted prevention strategies
- Precision Medicine Initiative
- predictive biomarkers
- preferred stock
- Premera Blue Cross
- premiums
- prescription drugs
- DTC advertising of
- spending, in US
- prescriptive analytics
- price
- concessions
- control
- flexibility
- attributes determining
- product factors determine
- models
- regulations, in major markets
- sensitivity
- strategy
- new, deployment of
- setting
- private insurance
- product
- attributes stakeholders prioritize
- development
- efficacy and safety
- pricing flexibility
- pricing strategy
- safety
- unproven real-world value at launch
- professional lifestyle coaches
- progression-free survival (PFS)
- Prolia (denosumab)
- promotion
- PROs. see patient-reported outcomes (PROs)
- Proscar (finasteride)
- protein coding regions
- proteome
- Proteus Digital Health
- providers
- financial accountability
- financially at-risk
- vertical integration
- public
- financing market
- health crisis
- health systems
- private partnership
- Qualcomm
- life ecosystem
- three lines of business
- licensing and acquisitions
- platforms
- venture investments
- Qualcomm Ventures
- quality of life
- quantified self
- QuintilesIMS
- radio frequency identification
- RAND team
- rare diseases
- R & D programs
- real-time data
- real-time intelligence
- real-world data
- real-world evidence
- real-world value
- red biotech
- redistributing reimbursement risk
- reference pricing decisions
- Regeneron Genetics Center (RGC)
- regional health systems
- regional price bands
- Reid, Jeffery
- reimbursement
- delays
- Remicade (infliximab)
- remote monitoring
- patient portals, role of
- Repatha (evolocumab)
- ResearchKit software
- Revlimid (lenalidomide)
- rheumatoid arthritis (RA)
- risk-sharing agreements
- Rituxan (rituximab)
- RNA interference (RNAi) technologies
- Robert Wood Johnson Foundation (RWJF)
- Roche
- Roche-Genentech relationship
- Sage Bionetworks
- salesforce strategies
- Samsung
- Sandoz
- Sanofi
- Sanofi digital portfolio in diabetes
- Sanofi Genzyme
- Sanofi-Regeneron alliance
- Sarbanes-Oxley Act
- Schadt, Eric
- Schleifer, Len
- scientific innovation
- scientific wellness
- segmentation (consumer, physician segments)
- semiautonomous payer committees
- sequencing technology
- shared decision making (SDM)
- shareholders
- sharing data
- Shaywitz, David
- Sherman, Michael
- Shire
- single payment access (SPA) scheme
- Small Business Innovation Research (SBIR) program
- small data
- smartphones
- social content risk assessment
- social media
- from insight mining to co-creating
- interactions
- sites
- Sovaldi (sofosbuvir)
- specialty drugs
- high-priced
- report, spending on
- specialty pharma companies
- specialty therapies
- Spence, Pamela
- Spritam (levetiracetam)
- Sprycel (dasatinib)
- stakeholders
- start-up biotech companies
- statistical analysis
- step-therapy
- strategic alliances
- deal terms
- exclusivity
- financial terms
- governance and dispute resolution
- intellectual property
- responsibilities
- scope
- term and termination
- dealing for
- mission and objectives
- monitoring results and learning
- partner selection
- structure
- in US and Europe
- process
- deal terms
- strategic payer engagement
- structured data
- super-consumers
- supply chain
- surgery, insurer offering medical coverage
- sustainability strategies
- addressing challenge of biosimilars
- building the market
- franchise building
- mature strategy
- portfolio diversification
- renewal strategies
- Tagrisso (osimertinib)
- vs. Iressa (gefitinib)
- Tarceva (erlotinib)
- target product profiles (TPPs)
- targeted
- cancer drugs
- medicines
- therapies
- taxpayer-funded national
- Tecentriq (atezolizumab)
- technographics
- Teladoc
- telehealth
- scope of services
- telemedicine, effectiveness of
- therapeutic innovations
- time-based bundled payment approach
- tools
- analytics
- Cloud-based analytics
- digital
- for outcomes-data capture
- geospatial mapping
- interactive
- predictive
- visual
- Toujeo (high-concentration glargine)
- TPPs. see target product profiles (TPPs)
- traditional
- financing model
- pharma pricing practices under pressure
- Tradjenta (linagliptin)
- transatlantic disparity, drug pricing
- transcriptome
- transportation industries
- true non-dilutive capital
- tumor biomarkers
- tumor characterization
- tyrosine kinase
- Bcr-Abl gene coding
- inhibitor aflibercept
- UCB
- UK’s National Institute for Health and Care Excellence (NICE)
- undisclosed discounts
- unit-based pricing methodology
- United Healthcare
- United States
- adopt European-style cost-effectiveness hurdles
- Affordable Care Act (ACA), creating new kinds of payers
- employers
- providers
- and European biotechnology
- capital raised
- initial public offerings (IPOs)
- drug pricing
- drug valuation tools
- financing market
- Food and Drug Administration (FDA)
- payer
- Europe, governments
- key types
- nongovernment
- offer prescription drug coverage to
- operate in isolation
- prescription drug coverage to citizens qualify for Medicare
- prioritizing value to control drug costs
- reimbursement
- UnitedHealthcare
- bundled payment program in oncology
- commercial insurers
- University of Washington
- unstructured data
- health
- urgency in payer community
- Value Labs
- value leakages
- value-added services
- value-based contracts
- work
- value-based healthcare
- value-based reimbursement
- value-creating event
- value-focused price not enough for Entresto
- Venter, J. Craig
- venture capital-backed companies
- venture capitalists
- venture philanthropy
- Cystic Fibrosis Foundation (CFF)
- model
- Vertex pharmaceuticals
- Verb Surgical
- Verily
- Vertex
- Veterans Health Administration (VA)
- Viagra (sildenafil)
- Victoza (liraglutide)
- Vioxx (rofecoxib)
- virgin territory
- voting equity securities
- Walgreens
- Wang, Jun
- Watson, James
- wearables
- biosensors
- sensors
- WebMD
- Welldoc
- white biotechnology
- whole genome sequencing
- Wilkins, Maurice
- Witty, Andrew
- World Health Organization (WHO)
- Xalkori (crizotinib)
- X-ray crystallography
- YouTube
- Zarxio
- Zocor (simvastatin)
..................Content has been hidden....................
You can't read the all page of ebook, please click here login for view all page.